Arthritis drug Remicade

J&J and Merck reach compromise on arthritis drug rights

April 19, 2011
Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi

Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …

GlaxoSmithKline OTC sale puts two plants on the block

April 19, 2011
Manufacturing and Production GSK, US, pharma manufacturing

GlaxoSmithKline’s decision to sell off a swathe of over-the-counter medicines means that a manufacturing facility in Memphis, Tennessee, has been …

Boehringer Ingelheim

Boehringer’s Pradaxa recommended for expanded European licence

April 18, 2011
Sales and Marketing Boehringer Ingelheim, CHMP, Pradaxa

Pradaxa is on course to expand its European licence with a recommendation from the CHMP for a new indication in …

knowledgepoint360_interphase_tim_mustill

Tim Mustill and Jenny Hepburn join InterPhase

April 18, 2011
Sales and Marketing appointment, sales and marketing

KnowledgePoint360 Group has appointed Tim Mustill and Jennifer Hepburn to key positions within its strategic consulting practice InterPhase. Tim has …

Pfizer

Phase III boost for Pfizer’s oral arthritis drug

April 18, 2011
Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …

TBA contamination prompts Topamax recall

April 18, 2011
Manufacturing and Production Johnson and Johnson, recalls

Another Johnson & Johnson business unit has decided to recall medicines because of a mouldy smell thought to be caused …

VBP: a fait accompli or room for manoeuvre?

April 18, 2011
Sales and Marketing value-based pricing

The pharma industry is seeking a compromise on the UK’s proposed value- based pricing, which promises to revolutionise the country’s …

Genzyme's headquarters

Genzyme MS drug shines in head-to-head trial with Rebif

April 18, 2011
Research and Development, Sales and Marketing Genzyme, Lemtrada, Sanofi-Aventis, relapsing multiple sclerosis

Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial. Five years’ worth of mid-stage data …

Fishawack gains industry experts

April 15, 2011
Medical Communications Fishawhack, PR

The Fishawack Group has gained industry experts Linda Harris and Jo Jarvis to expand its stakeholder relations and thought leader …

GlaxoSmithKline to drop Alli and other OTC products

April 15, 2011
Research and Development, Sales and Marketing Alli, GSK, OTC, Tyverb

GlaxoSmithKline is to sell off its weight loss drug Alli and other less profitable non-prescription drugs. GSK announced its decision …

Elliott maintains pressure on Actelion

April 15, 2011
Sales and Marketing Actelion, pharma mergers and acquisitions

Investment firm Elliott Advisors is maintaining its push for a new leadership team at Actelion.The investment firm is the biggest …

Lansley talks to nurse

Nurses’ vote of no confidence a further blow to Lansley

April 14, 2011
Health and Social Care Bill, NHS reforms, Royal College of Nursing

The Royal College of Nurses has voted overwhelmingly against Andrew Lansley’s health reforms, as he receives a vote of no …

Pharma manufacturing news in brief

April 14, 2011
Manufacturing and Production Cangene, Chirotech, Grand River Aseptic Manufacturing, Perrigo, West Pharmaceutical Services

India’s Dr Reddy’s Laboratories has opened a new headquarters for its UK subsidiary ChiroTech, along with a new purpose-built laboratory …

roche

Roche growth stalls after Avastin setback

April 14, 2011
Research and Development, Sales and Marketing Roche

Revenues at Roche flattened out in the first three months of 2011, as Avastin sales declined in the US and Europe. Group …

Watermeadow continues to grow

April 14, 2011
Research and Development Watermeadow, awards, employees, growth

Watermeadow Medical is delighted to welcome seven new staff to its UK offices. The appointments have been made as demand …

GP prescribing

GPs asked to squeeze drugs bill

April 14, 2011
Sales and Marketing AZ, GPs, NHS, NICE, prescribing

GPs are being asked not to prescribe NICE-approved drugs in order to cut costs.In the last year more than half …

Lonza, Slough

Lonza expands UK facility, bio business reports growth

April 13, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Benlysta, Lonza, Slough, manufacturing

Swiss contract manufacturer and fine chemicals company Lonza has said it plans to expand its biopharmaceutical production unit in Slough, …

FDA committee votes in Afinitor’s favour

April 13, 2011
Research and Development, Sales and Marketing

The FDA advisory committee has unanimously backed Novartis’ Afinitor for neuroendocrine tumours of pancreatic origin.  The recommendation comes from the …

ken_jones

Ken Jones appointed head of Astellas Europe

April 13, 2011
Astellas, Ken Jones

Astellas has appointed Ken Jones as its president and chief executive in Europe. Jones had been the chief operating officer …

Novartis ends phase III trial of Tasigna

April 12, 2011
GIST, Glivec, Novartis, Tasigna

Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …

The Gateway to Local Adoption Series

Latest content